FDA Hands Fast-Track Voucher for Kid's Rare Liver Fix
Published Date: 4/7/2026
Notice
Summary
The FDA just gave a special fast-track ticket called a Priority Review Voucher to Immedica Pharma AB for their rare pediatric disease drug, LOARGYS, approved in February 2026. This voucher helps speed up future drug reviews, benefiting patients with rare diseases and encouraging companies to develop more treatments. It’s a big win for kids with Arginase 1 Deficiency and could speed up new medicines hitting the market.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
New FDA Approval for ARG1‑D
The FDA approved LOARGYS (pegzilarginase-nbln) on February 23, 2026 to treat hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency. The drug is indicated to be used in conjunction with dietary protein restriction.
Priority Review Voucher Issued
The FDA issued a Priority Review Voucher to the sponsor, Immedica Pharma AB, tied to the approval of LOARGYS on February 23, 2026. The award is made under section 529 of the Federal Food, Drug, and Cosmetic Act to sponsors of approved rare pediatric disease product applications that meet certain criteria.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in